Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route

Vaccine

Volumn 25, Issue 4, 2007, Pages 719-728

  Tu, Cheng Fen ^a   Lin, Chi Chen ^a,b   Chen, Ming Chuan ^a   Ko, Tai Ming ^a   Lin, Chiu Mei ^c   Wang, Ying Chang ^d   Lai, Ming Derg ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^d BioWare Technologies Co Ltd   (Taiwan)

Author keywords

Autologous; Cancer; DNA vaccine; Intramuscular delivery; Neu; Xenogenic

Indexed keywords

AUTOLOGOUS NEU DNA VACCINE; CANCER VACCINE; DNA VACCINE; PROTEIN P185; SODIUM CHLORIDE; XENOGENIC NEU DNA VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MOUSE; EXPERIMENTAL NEOPLASM; FEMALE; GENE GUN; GENE THERAPY; HUMORAL IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T CELL DEPLETION;

ANIMALS; BIOLISTICS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2; SPECIES SPECIFICITY; URINARY BLADDER NEOPLASMS; VACCINES, DNA;

EID: 33845187439     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.009     Document Type: Article

References (50)

1. Pupa S.M., Tagliabue E., Menard S., and Anichini A. HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. J Cell Physiol 205 1 (2005) 10-18
2. Choudhury A., Charo J., Parapuram S.K., Hunt R.C., Hunt D.M., Seliger B., et al. Small interfering RNA (siRNA) inhibits the expression of the HER2/neu gene, upregulates HLA class I and induces apoptosis of HER2/neu positive tumor cell lines. Int J Cancer 108 1 (2004) 71-77
3. Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., and Fox J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 4 (Suppl. 12) (1999) 60-70
4. Warburton C., Dragowska W.H., Gelmon K., Chia S., Yan H., Masin D., et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10 7 (2004) 2512-2524
5. Osoba D., Slamon D.J., Burchmore M., and Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20 14 (2002) 3106-3113
6. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 26 4 Suppl 12 (1999) 71-77
7. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 5 (2002) 459-465
8. Grazette L.P., Boecker W., Matsui T., Semigran M., Force T.L., Hajjar R.J., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44 11 (2004) 2231-2238
9. Knutson K.L., Almand B., Dang Y., and Disis M.L. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 64 3 (2004) 1146-1151
10. Disis M.L., Gralow J.R., Bernhard H., Hand S.L., Rubin W.D., and Cheever M.A. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 156 9 (1996) 3151-3158
11. Nagata Y., Furugen R., Hiasa A., Ikeda H., Ohta N., Furukawa K., et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159 3 (1997) 1336-1343
12. Disis M.L., Schiffman K., Guthrie K., Salazar L.G., Knutson K.L., Goodell V., et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol 22 10 (2004) 1916-1925
13. Disis M.L., Goodell V., Schiffman K., and Knutson K.L. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24 5 (2004) 571-578
14. Rovero S., Amici A., Emma D.C., Bei R., Nanni P., Quaglino E., et al. DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165 9 (2000) 5133-5142
15. Chen Y., Hu D., Eling D.J., Robbins J., and Kipps T.J. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 58 9 (1998) 1965-1971
16. Amici A., Smorlesi A., Noce G., Santoni G., Cappelletti P., Capparuccia L., et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 7 8 (2000) 703-706
17. Wei W.Z., Shi W.P., Galy A., Lichlyter D., Hernandez S., Groner B., et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81 5 (1999) 748-754
18. Pilon S.A., Piechocki M.P., and Wei W.Z. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 167 6 (2001) 3201-3206
19. Pupa S.M., Iezzi M., Carlo E.D., Invernizzi A., Cavallo F., Meazza R., et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 65 3 (2005) 1071-1078
20. Renard V., Sonderbye L., Ebbehoj K., Rasmussen P.B., Gregorius K., Gottschalk T., et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 171 3 (2003) 1588-1595
21. Curcio C., Di Carlo E., Clynes R., Smyth M.J., Boggio K., Quaglino E., et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established HER-2/neu carcinomas. J Clin Invest 111 8 (2003) 1161-1170
22. Quaglino E., Iezzi M., Mastini C., Amici A., Pericle F., Di Carlo E., et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER-2/neu transgenic mice. Cancer Res 64 8 (2004) 2858-2864
23. Gallo P., Dharmapuri S., Nuzzo M., Maldini D., Iezzi M., Cavallo F., et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 113 1 (2005) 67-77
24. Lin C.C., Chou C.W., Shiau A.L., Tu C.F., Ko T.M., Chen Y.L., et al. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 10 2 (2004) 290-301
25. Lu Y., Wei Y.Q., Tian L., Zhao X., Yang L., Hu B., et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 170 6 (2003) 3162-3170
26. Pupa S.M., Menard S., Andreola S., and Colnaghi M.I. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53 24 (1993) 5864-5866
27. Fisk B., Blevins T.L., Wharton J.T., and Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181 6 (1995) 2109-2117
28. Disis M.L., Pupa S.M., Gralow J.R., Dittadi R., Menard S., and Cheever M.A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15 11 (1997) 3363-3367
29. Peoples G.E., Goedegebuure P.S., Smith R., Linehan D.C., Yoshino I., and Eberlein T.J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92 2 (1995) 432-436
30. Smorlesi A., Papalini F., Amici A., Orlando F., Pierpaoli S., Mancini C., et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24 11 (2006) 1766-1775
31. Serody J.S., Collins E.J., Tisch R.M., Kuhns J.J., and Frelinger J.A. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 164 9 (2000) 4961-4967
32. Ferlazzo G., Tsang M.L., Moretta L., Melioli G., Steinman R.M., and Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 195 3 (2002) 343-351
33. Marschner A., Rothenfusser S., Hornung V., Prell D., Krug A., Kerkmann M., et al. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol 35 8 (2005) 2347-2357
34. Roda J.M., Parihar R., and Carson III W.E. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175 3 (2005) 1619-1627
35. Carson W.E., Parihar R., Lindemann M.J., Personeni N., Dierksheide J., Meropol N.J., et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated HER2/neu-positive breast cancer cells. Eur J Immunol 31 10 (2001) 3016-3025
36. Zeng Y., Fest S., Kunert R., Katinger H., Pistoia V., Michon J., et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42 11 (2005) 1311-1319
37. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., and Falo Jr. L.D. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2 10 (1996) 1122-1128
38. + T cells after gene gun immunization. J Exp Med 188 6 (1998) 1075-1082
39. Zimmermann V.S., Bondanza A., Monno A., Rovere-Querini P., Corti A., and Manfredi A.A. TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens. J Immunol 172 4 (2004) 2643-2650
40. Ackerman A.L., and Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5 7 (2004) 678-684
41. + T cells. J Immunol 163 7 (1999) 3597-3604
42. Ratzinger G., Baggers J., de Cos M.A., Yuan J., Dao T., Reagan J.L., et al. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol 173 4 (2004) 2780-2791
43. Yu Z., Theoret M.R., Touloukian C.E., Surman D.R., Garman S.C., Feigenbaum L., et al. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 114 4 (2004) 551-559
44. Houghton A.N., and Guevara-Patino J.A. Immune recognition of self in immunity against cancer. J Clin Invest 114 4 (2004) 468-471
45. Shomura H., Shichijo S., Komatsu N., Matsueda S., Mine T., Rikimaru T., et al. Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients. Eur J Cancer 40 11 (2004) 1776-1786
46. Shomura H., Shichijo S., Matsueda S., Kawakami T., Sato Y., Todo S., et al. Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients. Br J Cancer 90 8 (2004) 1563-1571
47. Wolff J.A. The "grand" problem of synthetic delivery. Nat Biotechnol 20 8 (2002) 768-769
48. Sudowe S., Ludwig-Portugall I., Montermann E., Ross R., and Reske-Kunz A.B. Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses. Mol Ther 8 4 (2003) 567-575
49. Kim T.W., Lee J.H., He L., Boyd D.A., Hardwick J.M., Hung C.F., et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65 1 (2005) 309-316
50. Piechocki M.P., Pilon S.A., and Wei W.Z. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 259 1-2 (2002) 33-42